Get the Weekly Intelligence Brief — top committee picks every Sunday.

GMED vs MIRM

Globus Medical vs Mirum Pharmaceuticals, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
MIRM
Mirum Pharmaceuticals, Inc.
56
Watch
MetricGMEDMIRM
AI Score 71 56
Price $85.12 $98.27
P/E Ratio 21.45× -6.75×
ROE 11.8% -7.4%
Revenue Growth YoY
Gross Margin 68.5% 81.7%
Debt / Equity 0.02× -72.97×
Dividend Yield 0.0% 0.0%
RSI (14) 75.9 33.9
Beta 0.954 0.507
Expected Upside +0.1%

AI Committee View

Current Innellis committee reasoning for GMED versus MIRM.
GMED leads by 15 points.

GMED scores 71/100 (Buy) versus MIRM at 56/100 (Watch).

GMED Committee View
75% agreement
4 analysts

The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • RSI at 76 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
MIRM Committee View
50% agreement
6 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 44.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 13.0x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Revenue growing 44.0% YoY -- genuine top-line momentum — Growth
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price-to-book of 13.0x prices in significant intangible value — Value
  • ROE of only -289.3% -- cheap may mean cheap for a reason — Value
  • MACD histogram negative -- bearish momentum — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
GMED Full Analysis MIRM Full Analysis